A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Inclusion Criteria

• •Postmenopausal female between 18 and 70 years old
• •ECOG performance status of ≤ 1
• •Life expectancy more than 3 months
• •Histologically confirmed metastatic breast cancer
• •ER and\&or PR pqositive, HER2-negative
• •Disease progression during adjuvant or first-line endocrine therapy, or endocrine naive but unsuitable for endocrine therapy alone
• •No pretreated chemotherapy for metastatic disease
• •Have at least one target lesion according to RECIST 1.1
• •No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4 weeks before enrollment
• •Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10\^9/L, Platelet Count ≥ 75×10\^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance\>50ml/min